"The increased importance of intellectual property assets like patents and patent portfolios, along with the added complexity of valuing and analyzing risk for these information goods, has created a marketplace populated by players ill-equipped to handle the high transaction costs and information asymmetries representative of inteHectual property transactions. Accordingly, entities that can lower net transaction costs and improve information access will be able to take advantage of the unique nature of these assets." (Allen Wang, 2010, Berkeley Technology Law Journal, "Rise of the Patent Intermediaries") the tools atIPstreet.com could be a game changer.

"Reputation management is an important factor in attracting partners and external funding. From interviews with CEOs and CTOs of nine large industrial and publicly funded firms, we have a clear indication that a corporate R&D lab's well-managed reputation has a direct impact on the firm's brand value. In other words, corporate research labs should not be measured only by their technological outcome, but also by the impact they have on a firm's brand value," according to Gassman et al., 2009, Research Technology Management, "R&D Reputation and Corporate Brand Value." The tools IP Street offers will help you identify (1) patents that significantly influence your brand (2) why the patents are significant (3) Internally communicate what, why, and how a patent influences brand to get executive-level buy-in and (4) Communicate to your customers what, why, and how to further develop the brand's impact.

Myopia is generally what happens when unprecedented opportunities are placed before them. Those in the know generally do better than those in the worry. Consider Cetus, a startup biotech with a focus on a liver drug. The FDA delayed the approval of the drug, and a major funding crisis ensued. Chiron offered to take over the liabilities contingent on the sale of two patents (# 4,683,202 and # 4,683,195) to a third party, Roche Molecule for $300M (in 1993). This sale was stalled because DuPont challenged the validity of the patents, based on the formal claims written by the inventor (not a patent attorney), Kary Mullis. In the end, the soap opera turned out well for the investors with weak constitutions. For $300M, they sold the two patents to Roche, turned the company over to Chiron, and walked away. Kary Mullis won the Nobel prize for his invention embedded in these two patents, known as polymerase chain reaction (PCR) which allows DNA to be cloned. Over 4000 patents in biotech cite these original two patents. In our estimation, $300M represents "pennies on the dollar" valuation of these patents. The shareholders got a payday, and left the game. Roche on the other hand is thriving based on its intangible assets. Let IPstreet.com assist you.

Although subtle, there is a keen difference between invention and innovation. Utility represents this distinct difference between innovation and invention. Albeit important, inventors generally spend their fortunes on their ideas whereas innovators create fortunes from their ideas. Our goal is to help you become more than an inventor. Since innovation is generally considered the actualization of an invention, and we claim as a promise to innovate continuously, are we hypocrites? If we don't listen to you and develop tools, reports, and lenses that have meaning to you, indeed we would be. Only you can decide that for yourself. However, our commitment to you is to continue innovating tools and services that help you rationalize IP asset class. While previous analytical tools focused on finding data, our tools are built to help you both find and then undertand what you found. Our data and technologies are only vehicles to help us deliver on our promise — we create actionable business intelligence from patent documents.